Evidence mapPaperPMID 40328864Full record

ArticleScientific reports2025

IFITMs exhibit antiviral activity against Chikungunya and Zika virus infection via the alteration of TLRs and RLRs signaling pathways.

Nuttamonpat Gumpangseth, Paola Mariela Saba Villarroel, Abibatou Diack, Thanaphon Songhong, Sakda Yainoy, Rodolphe Hamel, Wipaporn Khanom, Phanit Koomhin, Chuchard Punsawad, Anon Srikiatkhachorn and 3 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Pharmaceuticals (Basel, Switzerland) · 2026
    Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Nuttamonpat GumpangsethDepartment of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Nakhon Pathom, Thailand.
Paola Mariela Saba VillarroelDepartment of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Nakhon Pathom, Thailand.
Abibatou DiackMIVEGEC, Univ. Montpellier, CNRS, IRD, Montpellier, France.
Thanaphon SonghongDepartment of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Nakhon Pathom, Thailand.
Sakda YainoyDepartment of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Nakhon Pathom, Thailand.
Rodolphe HamelDepartment of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Nakhon Pathom, Thailand.
Wipaporn KhanomMIVEGEC, Univ. Montpellier, CNRS, IRD, Montpellier, France.
Phanit KoomhinCenter of Excellence in Innovation on Essential Oil, Walailak University, Nakhonsithammarat, Thailand.
Chuchard PunsawadSchool of Medicine, Walailak University, Nakhonsithammarat, Thailand.
Anon SrikiatkhachornDepartment of Cell and Molecular Biology, Institute for Immunology and Informatics, University of Rhode Island, Providence, Rhone Island, USA.
Dorothée MisséMIVEGEC, Univ. Montpellier, CNRS, IRD, Montpellier, France.
Phoonthawee SaetearFlow Innovation-Research for Science and Technology Laboratories (Firstlabs), Bangkok, Thailand.
Sineewanlaya WichitDepartment of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Nakhon Pathom, Thailand. sineewanlaya.wic@mahidol.ac.th.

Funding

Agence Nationale de la Recherche ANR-17-CE15-00029Mahidol University MU-SRF-RS-05 A/66National Research Council of Thailand NRCT5-RGJ63012-125Office of the Permanent Secretary, Ministry of Higher Education, Science, Research and Innovation, Thailand RGNS 64-172Walailak University Wu-CGS-62002
6 · The paper itself

Abstract

Chikungunya virus (CHIKV) poses a significant challenge as there are currently no targeted antiviral drugs or vaccines to combat this infection. Here, we demonstrate that interferon-induced transmembrane proteins (IFITMs), including IFITM1, IFITM2, and IFITM3, which are interferon-stimulated genes (ISGs), inhibit CHIKV infection in human skin fibroblasts. Overexpression of IFITMs in cells restricts viral infection, whereas knockdown of IFITMs enhances viral infection. IFITMs overexpression causes a substantial upregulation of antiviral genes, namely TLR3, TLR7, TLR8, and TLR9, and their downstream signaling molecules such as TRADD, IRAK1, TRAF6, and MAP3K7, involved in TLRs signaling pathways. Furthermore, the DHX58 gene encoding the LGP2 protein, a negative regulator of RIG-I in RLRs signaling pathways, was downregulated in the overexpressed cells. Transcription factors including interferon regulatory factors (IRF) 3/5/7, which are downstream signaling components of both TLR and RLR signaling pathways, were also upregulated, resulting in enhanced IFNs signaling. IFITMs not only inhibits the early and late stages of viral infection but can also alter the antiviral innate-immune response to restrict CHIKV infection in human skin fibroblasts. Additionally, IFITMs exhibit their antiviral activity against Zika virus (ZIKV). Altogether, these results show the broad-spectrum antiviral property of IFITMs against arboviruses in foreskin cells.

Indexed as

Chikungunya FeverChikungunya virusMembrane ProteinsRNA-Binding ProteinsSignal TransductionToll-Like ReceptorsZika VirusZika Virus InfectionAntiviral AgentsCell LineDEAD Box Protein 58FibroblastsHumansVirus ReplicationAntiviral AgentsDEAD Box Protein 58Membrane ProteinsRNA-Binding ProteinsToll-Like ReceptorsArbovirusChikungunya virusIFITMsTLRs and RLRs signaling pathwaysZika virus

Identifiers

PMID40328864
PMCPMC12056003

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.